All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Top Biopharma Trends of 2021
    • Top Med-tech Trends of 2021
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, May 18, 2022
Home » Topics » Newco news, BioWorld Asia

Newco news, BioWorld Asia
Newco news, BioWorld Asia RSS Feed RSS

RNA
Newco news

Arrowhead and Vivo co-launch firm in China with $60M investment

May 3, 2022
By Doris Yu
No Comments
Arrowhead Pharmaceuticals Inc. and Vivo Capital LLC have launched a joint venture named Visirna Therapeutics for RNA interference therapeutics in the greater China market. Arrowhead is the majority shareholder of the new entity, while Vivo invested $60 million in the new entity.
Read More
Gold dollar sign inside gold cog
Newco news

Chimera going for ‘Gold’ as AFCR award boosts funding round

May 3, 2022
By David Ho
No Comments
Chimera Bioengineering Inc. has been selected as the winner of the Asian Fund for Cancer Research's (AFCR) 2021 BRACE Award Venture Competition, contributing $500,000 as part of a recent $7.5 million capital infusion and bringing to $26 million the company’s total amount raised to date.
Read More
Eye wireframe illustration
Newco news

‘Endo’ the line for CESED? Aurion cell therapy raises $120M

April 19, 2022
By Randy Osborne
No Comments
Aurion Biotech Inc. pulled down a $120 million financing to advance efforts with its lead candidate, a cell therapy for the treatment of corneal edema secondary to endothelial dysfunction (CESED).
Read More
Newco news

On heels of $70M series B round, China’s Medilink Therapeutics poised to enter clinic with ADC pipeline

March 29, 2022
By Tamra Sami
No Comments
After securing $70 million in series B funding, Chinese biotech Medilink Therapeutics Co. Ltd. is gearing up to enter the clinic with its next-generation antibody-drug conjugates (ADCs).
Read More
Elderly hands holding broken brain structure
Newco news

Aevisbio and NIH work to tackle neuroinflammation in Alzheimer's disease

March 8, 2022
By David Ho
No Comments
A new study from researchers at Aevisbio Inc. and the National Institutes of Health on the effect of 3,6’-dithiopomalidomide on neuroinflammation adds new detail to what might one day become a significant new therapeutic strategy to treat Alzheimer's disease and other neurological disorders.
Read More
Peanut allergy
Newco news

Prota Therapeutics achieves clinical remission of peanut allergy in phase IIb trial

March 1, 2022
By Tamra Sami
No Comments
PERTH, Australia – Prota Therapeutics Ltd.’s lead candidate PRT-120 induced clinical remission of peanut allergy in 51% of children in a phase IIb clinical trial. There are currently no curative therapies to treat food allergies, Prota Therapeutics CEO Mimi Tang told BioWorld. Peanut allergy in children can be particularly problematic because the only treatment is avoidance.
Read More
Servatus team
Newco news

Servatus advances live microbial biotherapeutics after AU$7.5M capital raise

Jan. 25, 2022
By Tamra Sami
No Comments
PERTH, Australia – After raising AU$7.5 million (US$5.4 million) in a private placement, biopharma company Servatus Ltd. is advancing its microbial biotherapeutics clinical programs targeting serious autoimmune conditions. The Coolum, Queensland-based private company is focused on identifying and developing live microbial biotherapeutics and engineered proteins to treat chronic and autoimmune diseases, as well as non-antibiotic treatments for bacterial infections.
Read More
Digital cancer cells illustration
Newco news

Binhui moves HSV-2-based oncolytic viral candidate toward U.S. trial

Aug. 31, 2021
By Doris Yu
No Comments
Binhui Biopharmaceutical Co. Ltd.’s BS-001, a recombinant human oncolytic herpes simplex virus type-2 expressing GM-CSF for the potential treatment of solid tumors, has gained an IND approval from the FDA.
Read More
Stem cells
Newco news

Hopstem targeting stroke with iPSC-derived human forebrain neural progenitor cell product

July 27, 2021
By Elise Mak
No Comments
With a special interest in neurological disorders, Hopstem Biotechnology Co. Ltd. closed a series A++ round to raise nearly ¥100 million (US$15.5 million) to advance hNPC-01, an off-the-shelf induced pluripotent stem cells (iPSC)-derived human forebrain neural progenitor cell product to treat chronic conditions caused by stroke and traumatic brain injuries.
Read More
Newco news

Suda Pharmaceuticals to combine new iNKT cell therapy platform with CARs to target blood cancers

July 20, 2021
By Tamra Sami
No Comments
PERTH, Australia – Suda Pharmaceuticals Ltd. saw its stock shoot up nearly 44% on the heels of an oversubscribed AU$3.65 million (US$2.71 million) capital raise after acquiring a new invariant natural killer T (iNKT) cell therapy platform for oncology.
Read More
Previous 1 2 3 4 5 Next

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 17, 2022.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech's briefs for May 17.
  • Hearing ear icon

    Cochlear to acquire rival Oticon Medical for $121M

    BioWorld MedTech
    Cochlear Ltd. will acquire Danish hearing implant company Oticon Medical A/S for AU$170 million (US$121 million) after parent company the Demant Group said it...
  • Illustration of cancer cells and immunotherapy treatment

    Former Genentech execs launch new immunotherapy biotech LTZ Therapeutics

    BioWorld
    After raising $17 million in seed funding, immunotherapy-focused biotech company, LTZ Therapeutics Inc., is announcing plans for the fledgling company whose...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Archives
    • Today's news
    • Search BioWorld Science
    • About
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing